Advertisement

Ads Placeholder
Loading...

Medesis Pharma S.A.

ALMDP.PAEURONEXT
Healthcare
Biotechnology
0.35
0.00(0.00%)
U.S. Market opens in NaNh NaNm

Medesis Pharma S.A. (ALMDP.PA) Stock Competitors & Peer Comparison

See (ALMDP.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ALMDP.PA€0.35+0.00%1.8M-0.59-€0.59N/A
UCB.BR€267.30+3.40%51B33.35€8.03+0.45%
ARGX.BR€657.00+5.83%40B37.90€17.04N/A
TUB.BR€220.00+3.77%9.7B104.31€2.09+0.41%
ABVX.PA€103.60+10.68%8.1B-21.12-€4.83N/A
GLPG.AS€25.62-2.14%1.7B5.35€4.85N/A
NANO.PA€27.50+6.38%1.4B-26.56-€1.09N/A
PHARM.AS€1.45+1.26%1B-145.90-€0.01N/A
MEDCL.PA€22.86+1.42%835.1M-38.13-€0.61N/A
IVA.PA€4.72-0.63%636.2M-2.41-€1.90N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ALMDP.PA vs UCB.BR Comparison April 2026

ALMDP.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALMDP.PA stands at 1.8M. In comparison, UCB.BR has a market cap of 51B. Regarding current trading prices, ALMDP.PA is priced at €0.35, while UCB.BR trades at €267.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALMDP.PA currently has a P/E ratio of -0.59, whereas UCB.BR's P/E ratio is 33.35. In terms of profitability, ALMDP.PA's ROE is +1.42%, compared to UCB.BR's ROE of +0.15%. Regarding short-term risk, ALMDP.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALMDP.PA.Check UCB.BR's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions